CD19-targeting CAR T Cells for Treatment of B Cell Malignancies : From Bench to Bedside
Immunotherapy for cancer is a young research field progressing at high speed. The first chimera of an antibody and a signaling chain was designed by Zelig Eshhar and was later further developed to enhance existing T cell therapy by combining a single-chain fragment of an antibody with the CD3 zeta c...
Main Author: | Karlsson, Hannah |
---|---|
Format: | Doctoral Thesis |
Language: | English |
Published: |
Uppsala universitet, Klinisk immunologi
2014
|
Subjects: | |
Online Access: | http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-232638 http://nbn-resolving.de/urn:isbn:978-91-554-9047-8 |
Similar Items
-
Novel CD37, Humanized CD37 and Bi-Specific Humanized CD37-CD19 CAR-T Cells Specifically Target Lymphoma
by: Vita Golubovskaya, et al.
Published: (2021-02-01) -
CAR-engineered NK cells; a promising therapeutic option for treatment of hematological malignancies
by: Faroogh Marofi, et al.
Published: (2021-07-01) -
Chimeric Antigen Receptors for T-Cell Malignancies
by: Lauren D. Scherer, et al.
Published: (2019-03-01) -
Different Subsets of T Cells, Memory, Effector Functions, and CAR-T Immunotherapy
by: Vita Golubovskaya, et al.
Published: (2016-03-01) -
From CAR-T Cells to CAR-NK Cells: A Developing Immunotherapy Method for Hematological Malignancies
by: Hui Lu, et al.
Published: (2021-08-01)